Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Opko

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s Ibrance over high cost

Draft guidance on breast cancer therapy calls for more evidence of its benefits

- PMLiVE

Novo Nordisk invests £115m in Oxford diabetes unit

But Danish pharma company admitted Brexit had made it a harder decision

- PMLiVE

Lilly pilots enhanced online trial information

Company aims to aid comprehension of the informed consent process

Pfizer invests in Swedish digital health firm

AMRA's technology transforms MRI images into precise fat and muscle measurements 

Deal Watch December 2016

Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up

Strategic symbionts

Strategic alliances are becoming more interesting and more important 

AstraZeneca AZ

AZ tweaks immuno-oncology trials as it chases lung cancer leaders

Toughens targets for durvalumab in NSCLC monotherapy and combination study

Allergan logo

Allergan plans to file oral uterine fibroid drug in US by year-end

Analysts predict treatment will reach blockbuster sales as phase III trials meet objectives

Biogen Idec building

Biogen proffers new data to support high-priced Spinraza

Trial demonstrates statistically-significant risk reduction in paediatric SMA for potential blockbuster drug

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

Novo signs personalised digital health deal in diabetes

Will work with Glooko on jointly-developed and branded solutions

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links